Institute of Bioorganic Chemistry  

Medicinal product - antitumor drug Pemetrexed and technology for producing the substance










Linked profile in other language
Aleksej Yantsevich
+375 17 357 8761
The Institute of Bioorganic Chemistry offers consumers a medicinal product - the antitumor drug Pemetrexed on the basis of a manufacturing agreement, a technology for obtaining a substance on the basis of a license agreement and is looking for partners to conclude a distribution services agreement.
Pemetrexed disodium salt heptahydrate, pharmaceutical substance Pemetrexed, lyophilized powder for solution for infusion 500 mg. Antineoplastic agent, an analog of folic acid, antimetabolite, used for the treatment of locally advanced or metastatic non-squamous cell non-small cell lung cancer as the first line of therapy (in combination with cisplatin), for the treatment of previously treated patients (in mono-mode), as well as supportive therapy in patients with the non-progressive disease after primary therapy with platinum drugs.

A pilot production technology has been developed and the pharmaceutical substance Pemetrexed is registered disodium salt heptahydrate (FSP RB 2050-15; RU No. 15/02/2340).

A finished dosage form of Pemetrexed has been developed and registered (FSP RB 2099-15; RU No. 15/06/2401).
Advantages and Innovations
It is used in the treatment of inoperable pleural mesothelioma, in combination with platinum preparations.
Stage of development
Already on the market
Funding source
State budged
IPR status
Exclusive rights
Secret know-how
Sector group

Client information

R&D institution
Year established
NACE keywords
C.20.59 - Manufacture of other chemical products n.e.c.
C.21.10 - Manufacture of basic pharmaceutical products
C.21.20 - Manufacture of pharmaceutical preparations
M.72.19 - Other research and experimental development on natural sciences and engineering
M.74.90 - Other professional, scientific and technical activities n.e.c.
Turnover (in EUR)
Already engaged in transnational cooperation
Additional comments
The institute has an experimental base for studying the biological activity of the obtained compounds at the cellular level and in tests on animal models. For pilot production of the developed products (hemosorbents, preparations of recombinant enzymes, immunochemical reagents, oxyphitosterols, etc.), 5 experimental production sites have been created at the institute.

The results of fundamental and applied research on methods and means of protecting plants from diseases, insects, weeds, and other unfavorable environmental factors that are safe for humans and the biosphere as a whole were the basis for the development of methods for obtaining new plant growth stimulators, pheromone compositions (pheromones of the codling moth LP -U and mill moth), active ingredients of pesticides (analogs of the herbicide Grasp and insecticide Confidor), formulations of pesticides (herbicides, insecticides, fungicides, etc.).

The created intellectual property of the Institute today consists of patents maintained in force, laboratory technological and experimental industrial regulations, technical specifications, and trademarks. Licensing agreements are in force for the transfer of technologies for the production of immunodiagnostic products, hemosorbents and pesticides to manufacturers.
Languages spoken

Information about partnership

Type of partnership considered
Distribution services agreement
License agreement
Manufacturing agreement
Type and role of partner sought
Consumers interested in purchasing the anticancer drug Pemetrexed under a manufacturing agreement.

Distributors interested in purchasing the anticancer drug Pemetrexed under a distribution services agreement.

Partners interested in acquiring technology for obtaining the substance of the anticancer drug Pemetrexed under a license agreement.
Type and size of partner sought
> 500 MNE
> 500
SME 51-250
SME 11-50
SME <= 10
R&D Institution


Количество уникальных просмотров в одной сессии: 859
Статистика ведется с 13.01.2022 15:25:40